Stay updated on Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial

Sign up to get notified when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The updates appear to be minor formatting and text edits on the Study Details page, with no changes to the primary outcomes, study design, enrollment, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-02T00:37:56.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Upgrade to v3.2.0 with a new operating-status notice about government funding and a link to operating status details; removes v3.1.0 reference.
    Difference
    3%
    Check dated 2025-10-04T11:11:10.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-27T07:24:18.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Updated the page from Revision: v3.0.1 to Revision: v3.0.2; removed the old revision tag and the 'Back to Top' element.
    Difference
    0.2%
    Check dated 2025-09-12T23:39:11.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-05T19:32:30.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, specifically retaining the name and location of Mt. Pleasant, South Carolina, while also adding drug information for Risankizumab and its relevance to skin and connective tissue diseases.
    Difference
    1%
    Check dated 2025-08-29T15:43:28.000Z thumbnail image

Stay in the know with updates to Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Risankizumab in Psoriasis: New Formulation Clinical Trial page.